FDA Approves Medtronic's DBS Therapy for Drug Resistant Epilepsy

Medtronic plc (NYSE:MDT)  announced on 5/1/18 that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic's Deep Brain Stimulation (DBS) therapy as adjunctive treatment for reducing the frequency of partial-onset seizures, in individuals 18 years of age or older who are refractory, or drug-resistant, to three or more antiepileptic medications.